Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

Research Partnership

- PMLiVE

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Approximately 400 patients are expected to benefit from the treatment in England and Wales annually

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

- PMLiVE

Improving outcomes in oncology: patient centricity and mental health

A key challenge in healthcare is how to proactively address unmet needs using patient-centric campaigns and resources, particularly in a time when ‘in-person’ care is limited. How can this be...

Mednet Group

- PMLiVE

World Cancer Day – February 2022

World Cancer Day is celebrated around the world in February in February and innovative Trials wants to take this opportunity to raise awareness around cancer

Innovative Trials

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients

The combination significantly reduces cancer recurrence by approximately 37% and reduces secondary breast cancer by 39%

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

New drug available on NHS will benefit lung cancer patients

Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1,000 patients in year...

- PMLiVE

FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links